Mutagenicity of hydroxyurea in lymphocytes from patients with sickle cell disease
AUTOR(ES)
Khayat, André Salim, Guimarães, Adriana Costa, Cardoso, Plínio Cerqueira, Lima, Patrícia Danielle Lima de, Bahia, Marcelo de Oliveira, Antunes, Lusânia M. Greggi, Burbano, Rommel Rodríguez
FONTE
Genetics and Molecular Biology
DATA DE PUBLICAÇÃO
2004
RESUMO
Hydroxyurea is commonly used in the treatment of myeloproliferative diseases and in patients with sickle cell disease (SCD). The use of this antineoplastic agent in patients with SCD is justified because of the drug's ability to increase fetal hemoglobin levels, thereby decreasing the severity of SCD. However, high doses or prolonged treatment with hydroxyurea can be cytotoxic or genotoxic for these patients, with an increased risk of developing acute leukemia. This danger can be avoided by monitoring the lymphocytes of patients treated with hydroxyurea. Cytogenetic tests are important endpoints for monitoring the physiological effects of physical and chemical agents, including drugs. In this work, we assessed the genotoxicity of hydroxyurea in short-term cultures of lymphocytes from SCD patients. Hydroxyurea was not cytotoxic or genotoxic at the concentrations tested in the G2 phase of the cell cycle. These results support the use of hydroxyurea in the treatment of SCD, although further work is necessary to understand the effects of this drug in vivo.
Documentos Relacionados
- Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease
- Patients with sickle cell disease taking hydroxyurea in the Hemocentro Regional de Montes Claros
- Hematological differences between patients with different subtypes of sickle cell disease on hydroxyurea treatment
- Standardization method for measurement of hydroxyurea by Ultra High Efficiency Liquid Chromatography in plasma of patients with sickle cell disease
- Effect of hydroxyurea on G gamma chain fetal hemoglobin synthesis by sickle-cell disease patients